Kuros Biosciences【0RHR】銘柄情報

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

8.56

( - )

買値

8.56

売値

8.56

出来高

74,659

0.00 日の範囲 0.00

8.56 52 週間の範囲 8.56

時価総額

337.601M

前日終値

8.56

始値

時刻

416

18.455

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

CHF 196,600

発行済株式数

39,439,421

配当利回り

PER

424.24

1 株当たり利益 (EPS)

0.06

歳入

146.06M

純利益

2.55M

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Gran... Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

kurosbio.com

本社

Schlieren, Switzerland

設立

2026

Kuros Biosciences AG is listed in the sector of the ロンドン証券取引所 with ticker 0RHR. The last closing price for Kuros Biosciences was CHF8.56. Over the last year, Kuros Biosciences shares have traded in a share price range of CHF 8.56 to CHF 8.56.

Kuros Biosciences currently has 39,439,421 shares in issue. The market capitalisation of Kuros Biosciences is CHF337.60 million. Kuros Biosciences has a price to earnings ratio (PE ratio) of 424.24.

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Kuros...

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Annual General Meeting of Kuros Biosciences approves all resolutions...

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Ad hoc announcement pursuant to Article 53 of the...

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Ad-hoc announcement pursuant to Article 53 of the...

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences Kuros Biosciences to provide investor updateat Octavian and...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual...

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 Ad hoc...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Kuros Biosciences debuts commercial launch of MagnetOs...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	8.56	8.56	8.56	16173	8.56	DE
52	8.56	8.56	8.56	15645	8.56	DE
156	8.56	8.56	8.56	10146	8.56	DE
260	8.56	8.56	8.56	5946	8.56	DE

0RHR - Frequently Asked Questions (FAQ)

What is the current Kuros Biosciences AG share price?

The current share price of Kuros Biosciences AG is CHF 8.56

How many Kuros Biosciences AG shares are in issue?

Kuros Biosciences AG has 39,439,421 shares in issue

What is the market cap of Kuros Biosciences AG?

The market capitalisation of Kuros Biosciences AG is CHF 337.6M

What is the 1 year trading range for Kuros Biosciences AG share price?

Kuros Biosciences AG has traded in the range of CHF 8.56 to CHF 8.56 during the past year

What is the PE ratio of Kuros Biosciences AG?

The price to earnings ratio of Kuros Biosciences AG is 424.24

What is the cash to sales ratio of Kuros Biosciences AG?

The cash to sales ratio of Kuros Biosciences AG is 6.87

What is the registered address of Kuros Biosciences AG?

The registered address for Kuros Biosciences AG is Wagistrasse 25, Schlieren, Zurich, 8952

What is the Kuros Biosciences AG website address?

The website address for Kuros Biosciences AG is kurosbio.com

PutzMueler 5分前

Booooo. I won’t vote yes to any bid lower than our highest share price ever.

And that would be somewhere around $18, which happens to be close to the target for Mark Smith to call out all the warrants to exercise, after 30 days

Time enough for me to bail out on a high n

PutzMueler 5分前

JACKPOT 5分前

Im holding...took me a while to get my .0001 shares

TLSS

Wehalls 6分前

Provectus 2026 Annual Shareholders Meeting Notes

EXECUTIVE SUMMARY

The overall tone of the meeting was highly optimistic. Management repeatedly emphasized that Provectus now believes it understands most of Rose Bengal's mechanism of action (MOA), has established me

PVCT

manibiotech 6分前

“Absolutely correct Doc. The delay is all about the manufacturing (C suite and Flaskworks readiness) ”

With construction paused for who knows for what duration in last filing , it will be months before completion and validation . I sure hope that’s not the case

NWBO

gemstone57 7分前

MVNT

MrGoldTooth 11分前

It's a smoking deal for a company that has the funding to build it out and harvest the ore. An offer of $15 per share SHOULD be accepted, perhaps even $12 per share. It would more than likely be offered in cash and shares. Smith hasn't been able to get 'er done, nor has he been able to lift the P

Lord Andreti 13分前

Ok the NOL cannot be utilized now as is. What if the company though starts doing business? Legitimate and continuous business. Can’t they carry it over for future profits?

What happens if they get acquired or merge with some other company that has already been doing legit business? C

VGLS

Chuck McQuade 14分前

*raises hand*

VGLS

misterfishman 15分前

If and when the bid and ask is at .0001 again then i fill my boat again.

CNBX

PutzMueler 15分前

I’m a firm believer there will be a bidding war after we know what is in the ground.

Remember Make in America. CBMM Niobium
They on-shore because of Niobium the rest is easy sell

But as it stands right now, it seems like Traxys is going to get everything and th

Chuck McQuade 15分前

I asked a couple of different systems.

The "zero asset" argument he is making only applies if the incoming company liquidates everything and changes the entire nature of the business model.
Section 382 explicitly states that the NOL is not destroyed if the company satisfies th

VGLS

Eli's Gone 21分前

GL all...

ergo sum 22分前

Looking for a pull back here to get some shares.

Doc logic 24分前

jesster64,

No one else produces DCs with the same qualities that NWBO is seeking. DCs are not just universal in activation/maturation. Little tweaks make a big difference as Dr. Kalinski has proven. So, when you get past the noise about who can do what, the focus all comes back to

NWBO

Forensics888 24分前

Fraud is fraud and I don't condone fraud - but many do.

FMCC

Homebrew 25分前

ZNOG has years of drilling "performances" 😆 🤣
Zion has re-entered the well

ZNOG

InvestInBiel 27分前

https://electrome.com/team

BIEL

Red Cloud 28分前

Your point regarding "is the market wrong" would make more sense if Fannie and Freddie were not trading on the OTC market, which many here have opined happens to be insufficiently regulated, enforced, a combination thereof, or otherwise corrupt. In your post you refer to "manipulating the OTC", and

FNMA

Farmboynate 31分前

He's been texting me to ask me to agree to it by tomorrow so they can have a merger move forward or something I told him they need to do it the right way buyback retire shares, convert shares to Preferred,... do a merger and if its a good enough candidate then after all this is done they R/S

FUNR

flipper44 32分前

Yes, and he’s speaking to the correct immediate audience. Mostly UK Neurosurgeons, Neurologists, Oncologists, Researchers, Nurses, Patient Advocates, Regulators and other Biotech Represetatives.

NWBO

TightCoil 32分前

your post wasn't as coherent as in the past.
must be restructuring mechanics interference

FNMA

Genz2 33分前

Elon Musk is more than 100 times richer than Donald Trump!!! That’s pretty scary!!!! Is he smart or crazy to own Bitcoin???

BTCUSD

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Kuros Biosciences AG (0RHR)

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Kuros Biosciences AG について

0RHR 最新ニュース

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

0RHR - Frequently Asked Questions (FAQ)

0RHR 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する